The IVIM Health lawsuit currently drawing attention is Olita v. IVIM Services, LLC, a class action filed in federal court in Michigan, but it is only one piece of the pressure on the telehealth weight-loss company: IVIM also received an FDA warning letter in February 2026 for misbranding its compounded GLP-1 products, and it has drawn more than a hundred Better Business Bureau complaints over billing, refunds, and undelivered medication.
The Olita Class Action
Olita v. IVIM Services, LLC was filed in the U.S. District Court for the Eastern District of Michigan, Case No. 2:25-cv-14019, and assigned to Judge Robert J. White. The docket classifies it as a personal injury case, and the plaintiff class is represented by the Almeida Law Group.1Law360. Olita v. IVIM Services, LLC The case is active. There has been no ruling on class certification, no settlement, and no dismissal on the public docket, and detailed allegations have not been made widely available.2Law360. Olita v. IVIM Services, LLC – Dockets
One structural fight is likely to come early. IVIM’s terms and conditions include a mandatory binding arbitration clause and a class action waiver, which purport to require customers to bring disputes individually in arbitration rather than as a class in court.3Ivím Health. Terms and Conditions Whether that clause knocks the case out of federal court, or is challenged and set aside, is the first question the litigation is likely to answer.
The FDA Warning Letter
On February 20, 2026, the FDA issued a warning letter to IVIM Services LLC over how the company labels its compounded semaglutide and tirzepatide products. During a December 2025 review, the agency found that IVIM’s website displayed “Ivim” on product labels as if IVIM were the manufacturer. IVIM does not compound the drugs itself; independent, licensed compounding pharmacies do. Under federal regulations, putting a company’s name on a drug label without qualifying language represents that company as the manufacturer, and the FDA said that misrepresentation violated the Federal Food, Drug, and Cosmetic Act.4U.S. Food & Drug Administration. Warning Letter: IVIM Services LLC dba Ivim
The letter gave IVIM 15 working days to respond with a plan to correct the violations, name the actual compounding pharmacies producing its products, and address other potentially misleading claims on the website. IVIM’s own site notes that its compounded medications are “prepared by independent, licensed compounding pharmacies” and are not FDA-approved.5Ivím Health. Ivím Health
IVIM was one of 30 telehealth companies to receive a warning letter that day. The FDA announced the batch publicly on March 3, 2026, with Commissioner Marty Makary saying the agency was “paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms.”6U.S. Food & Drug Administration. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s It was the second such round of letters since the initiative began in September 2025.7Fierce Pharma. FDA Ramps Crackdown on GLP-1 Drug Compounders With Fresh Batch of 30 Warning Letters
Consumer Complaints About Billing and Delivery
Beyond the courtroom, IVIM has accumulated a substantial paper trail of consumer complaints. The Better Business Bureau lists 101 complaints against IVIM Services LLC over the past three years, with 59 filed in the most recent 12 months. The top categories are billing issues (33), product issues (30), and delivery problems (11).8Better Business Bureau. IVIM Services LLC Complaints
The patterns repeat. Customers say they were charged the $75 monthly membership fee after they thought their account was closed or treatment had ended. Others describe being quoted a set price for a multi-month medication package, then seeing the terms or price shift mid-contract. When customers ask for refunds on medication that never arrived or check-ins that never happened, the company frequently refuses or imposes cancellation fees of up to $200.8Better Business Bureau. IVIM Services LLC Complaints
Product and delivery complaints track the same shape. Several customers report that the monthly doctor check-ins the $75 fee is supposed to cover never took place. Others describe formulations changed without notice, delivery schedules moved from three-month to two-month cycles without explanation, and shipments that simply did not arrive.9Better Business Bureau. IVIM Services LLC Complaints – Page 4
Of the 101 complaints, 51 were resolved to the customer’s satisfaction, and 50 were marked “answered” — meaning IVIM replied but the customer did not accept the resolution or did not follow up. IVIM still holds an A+ BBB rating and is BBB Accredited.8Better Business Bureau. IVIM Services LLC Complaints
Why Refunds Are So Hard to Get
Much of the complaint volume tracks the fine print. IVIM’s refund policy states that prescription medications are “non-refundable” regardless of usage, time in the program, or whether the membership has been canceled. Medical devices such as scales are also non-refundable. The only products eligible for return are unopened supplements within 30 days of delivery. Damaged or lost shipments must be reported within 72 hours, and the company states that its “determination is final subject to applicable law.”10Ivím Health. Refund and Returns Policy
The terms and conditions add more. Refunds for unshipped medication carry administrative fees of $100 per undeveloped three-month portion or $50 per undeveloped two-month portion. The terms also impose a one-year statute of limitations on any legal dispute and cap IVIM’s liability at whatever the customer paid in the six months before making a claim.3Ivím Health. Terms and Conditions
What to Do If You’re an IVIM Customer
If you have an active membership and want out, cancel through the account channels and keep dated screenshots of the cancellation and any confirmation email; complaints repeatedly describe charges continuing after customers believed they had closed the account. If you are billed after cancellation, dispute the charge with your card issuer — that route is outside IVIM’s refund policy and its arbitration clause.
If you paid for medication or check-ins you did not receive, file a complaint with the Better Business Bureau; the file shows roughly half of complainants received a resolution that way. Save the shipping records, the prescription package terms you were quoted, and any promises about provider visits. Keep in mind the contractual traps: the one-year deadline to bring a claim, the six-month liability cap, and the arbitration and class-waiver language you agreed to at signup.3Ivím Health. Terms and Conditions
If you believe you were injured by a compounded medication, report the adverse event to the FDA and speak with a lawyer before signing any release the company offers as part of a refund.
Eli Lilly Has Not Sued IVIM
One point of frequent confusion: Eli Lilly, the maker of Mounjaro and Zepbound, has not sued IVIM. In April 2025, Lilly did sue four other telehealth companies that sold compounded tirzepatide — Mochi Health, Fella Health, Willow Health, and Henry Meds — in the Northern District of California, alleging false advertising under the Lanham Act, unfair competition under California law, and violations of California’s corporate practice of medicine rules.11STAT News. Eli Lilly Sues Telehealth Firms Over Corporate Practice of Medicine, GLP-1 Prescriptions A California judge dismissed the case against Willow Health, finding Lilly had not shown sufficient evidence of lost sales or reputational harm; the Henry Meds case remains pending, and the Mochi and Fella cases are in early stages.12Alliance for Pharmacy Compounding. Judge Dismisses Lilly Suit IVIM is not a defendant in any of those cases.
The Wider Squeeze on Compounded GLP-1s
IVIM’s problems sit inside a broader shift. The FDA removed tirzepatide from its drug shortage list in December 2024 and semaglutide in February 2025, cutting off the legal basis that had let compounding pharmacies produce cheaper versions of both drugs.13U.S. Food & Drug Administration. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize Industry challenges to those delistings in the Northern District of Texas failed at the trial level, and the Fifth Circuit heard oral argument in the tirzepatide appeal in March 2026 but has not yet ruled.14Courthouse News Service. Fifth Circuit Probes FDA Ban on Compounded GLP-1s
In April 2026, the FDA went further, proposing to formally exclude semaglutide, tirzepatide, and liraglutide from the list of bulk substances that outsourcing facilities can use for compounding. Public comments closed on June 29, 2026.15U.S. Food & Drug Administration. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide From 503B Bulks List Whichever way that proposal and the Fifth Circuit appeal come out, the legal room for the compounded GLP-1 business model IVIM has built its membership around is narrowing.